IRWD — Ironwood Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $589.91m
- $895.78m
- $296.15m
Ironwood Pharmaceuticals Q2 revenue beats expectations
Ironwood Pharmaceuticals Inc expected to post earnings of 4 cents a share - Earnings Preview
Ironwood Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Ironwood Pharmaceuticals Inc expected to post a loss of 1 cent a share - Earnings Preview
U.S. RESEARCH ROUNDUP- CNB Financial, Disney, Triumph Group
Brief: Ironwood Pharmaceuticals Provides Clinical And Regulatory Update On Apraglutide
Google launches new Ironwood chip to speed AI applications (updated)
Ironwood Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Ironwood Pharmaceuticals Inc expected to post earnings of 8 cents a share - Earnings Preview
Ironwood Pharmaceuticals Inc expected to post earnings of 8 cents a share - Earnings Preview
Ironwood Pharmaceuticals Inc expected to post earnings of 8 cents a share - Earnings Preview
Ironwood Pharmaceuticals Inc expected to post earnings of 8 cents a share - Earnings Preview
Brief: Ironwood Pharmaceuticals Inc - Board Approves 50% Workforce Reduction
Ironwood Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
Brief: Ironwood Pharmaceuticals Q3 Revenue USD 91.592 Million Vs. IBES Estimate USD 91.2 Million
Brief: Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics And Disease Characteristics In Adults With Short Bowel Syndrome With Intestinal Failure (Sbs-If), According To New Stars Phase Iii Data From Ironwood At Acg 2024
Brief: Ironwood Pharmaceuticals Q2 Revenue USD 94.396 Million Vs. IBES Estimate USD 107 Million
Ironwood Pharmaceuticals Inc expected to post earnings of 15 cents a share - Earnings Preview